title: Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.
abstract: BACKGROUND
  Protocadherin8 has been demonstrated to play critical roles in initiation and progression of several human cancers. It is frequently inactivated by promoter methylation in cancers and may be used as a potential biomarker. However, the methylation status of protocadherin8 and its clinical significance in prostate cancer remains largely unknown. The purpose of this study was to evaluate the clinical significance of protocadherin8 methylation in early-stage prostate cancer.
  
  
  METHODS
  The promoter methylation status of protocadherin8 in 162 prostate cancer tissues and 47 normal prostate tissues was examined using methylation-specific PCR (MSP). Subsequently, the relationships between protocadherin8 methylation and clinicopathological features of prostate cancer patients and biochemical recurrence-free survival of patients were analyzed.
  
  
  RESULTS
  We found that protocadherin8 methylation occurred frequently in prostate cancer tissues but not in normal prostate tissues. Moreover, protocadherin8 methylation was significantly associated with advanced pathologic stage, higher level of preoperative prostate specific antigen (PSA), higher Gleason score, positive lymph node metastasis, and biochemical recurrence. In addition, patients with protocadherin8 methylated have shorter biochemical recurrence-free survival time than patients without. Multivariate Cox regression analysis revealed that protocadherin8 methylation was an independent predictor of biochemical recurrence-free survival in prostate cancer patients.
  
  
  CONCLUSIONS
  Promoter methylation of protocadherin8 is a frequent event in prostate cancer, and might be used as an independent prognostic factor for biochemical recurrence-free survival in patients with prostate cancer.
authors.affiliation: Department of Urology, First Hospital of Jiamusi University, Jiamusi, Heilongjiang, China (mainland).
authors.forename: Wen-Bin
authors.initials: WB
authors.lastname: Niu
authors.affiliation: Department of Urology, First Hospital of Jiamusi University, Jiamusi, Heilongjiang, China (mainland).
authors.forename: Shi-Liang
authors.initials: SL
authors.lastname: Gui
authors.affiliation: Department of Urology, Affiliated Xuzhou Hospital of Jiangsu University (Xuzhou Cancer Hospital), Xuzhou, Jiangsu, China (mainland).
authors.forename: Ying-Li
authors.initials: YL
authors.lastname: Lin
authors.affiliation: Health Science Center, Jiangsu University, Zhenjiang, Jiangsu, China (mainland).
authors.forename: Xing-Li
authors.initials: XL
authors.lastname: Fu
authors.affiliation: Department of Urology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Ma
authors.affiliation: Department of Urology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
authors.forename: Wen-Ping
authors.initials: WP
authors.lastname: Li
mesh_terms: D000368:Aged; D015820:Cadherins / Q000235:genetics*; D019175:DNA Methylation / Q000235:genetics*; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000235:genetics*; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D011379:Prognosis; D011401:Promoter Regions, Genetic; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology*; D000091363:Protocadherins
chemical_list: D015820:Cadherins; C115816:PCDH8 protein, human; D000091363:Protocadherins